Health Technology Assessment Area-AETSA, Andalusian Public Foundation for Progress and Health ("Fundación Progreso y Salud"-"FPS"), Seville, Spain.
Research Group HUM604: Lifestyle Development in the Life Cycle and Health Promotion, University of Huelva, Huelva, Spain.
PLoS One. 2023 Feb 9;18(2):e0281573. doi: 10.1371/journal.pone.0281573. eCollection 2023.
NKX2-1-related disorders have a prevalence of 1:500,000 and are therefore considered a rare condition according to the European Commission's definition. The European Reference Network of Rare Neurological Disorders is developing the first clinical practice guideline on the management of this condition, with the support of the Andalusian Health Technology Assessment Area, Endo-ERN, ERN-Lung and Imegen, within the framework of the ERNs Guidelines programme (DG SANTE/2018/B3/030). Within the scope of this programme, it becomes necessary to explore the patient perspective in order to include it in the ongoing clinical practice guideline and accompanying patient information booklet.
This study will use qualitative methods to explore the values, preferences and information needs of patient with NKX2-1-related disorders and their caregivers. Participants will come from a variety of countries throughout Europe. One focus group and four semi-structured interviews will be conducted. Pairs will analyse the data using Grounded Theory. The Andalusian Regional Ministry of Health's Ethics Coordinating Committee for Biomedical Research (Sevilla, Andalucía, Spain) has approved this study protocol (29/03/2022).
This is the first study to explore the values, preferences, and information needs of patients with NKX2-1-related disorders. The proposed study's findings will contribute to the generation of useful knowledge that will provide guidance to improve the care given to patients with the studied condition. While this study will provide valuable insights into the perspectives of patients with NKX2-1-related disorders, the findings are unlikely to be generalizable to patients with other conditions.
根据欧盟委员会的定义,NKX2-1 相关疾病的患病率为 1:500000,因此被认为是一种罕见疾病。罕见神经疾病欧洲参考网络正在制定该疾病管理的首个临床实践指南,得到了安达卢西亚卫生技术评估区、Endo-ERN、ERN-Lung 和 Imegen 的支持,该指南是在 ERNs 指南计划(DG SANTE/2018/B3/030)框架内开展的。在此计划范围内,有必要从患者角度进行探索,以便将其纳入正在进行的临床实践指南和伴随的患者信息手册中。
本研究将采用定性方法探索 NKX2-1 相关疾病患者及其照顾者的价值观、偏好和信息需求。参与者将来自欧洲各地的多个国家。将进行一次焦点小组和四次半结构化访谈。配对将使用扎根理论分析数据。安达卢西亚地区卫生部生物医学研究伦理协调委员会(西班牙塞维利亚)已批准本研究方案(2022 年 3 月 29 日)。
这是第一项探索 NKX2-1 相关疾病患者价值观、偏好和信息需求的研究。拟议研究的结果将有助于产生有用的知识,为改善对所研究疾病患者的护理提供指导。虽然本研究将为 NKX2-1 相关疾病患者的观点提供有价值的见解,但研究结果不太可能推广到其他疾病患者。